Compare TBBK & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TBBK | IRON |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.4B |
| IPO Year | 2004 | N/A |
| Metric | TBBK | IRON |
|---|---|---|
| Price | $69.01 | $90.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $68.00 | ★ $108.83 |
| AVG Volume (30 Days) | 469.0K | ★ 560.9K |
| Earning Date | 01-29-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.10 | N/A |
| EPS | ★ 4.78 | N/A |
| Revenue | ★ $523,163,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $32.53 | N/A |
| P/E Ratio | $14.38 | ★ N/A |
| Revenue Growth | ★ 10.84 | N/A |
| 52 Week Low | $40.51 | $30.82 |
| 52 Week High | $81.65 | $99.50 |
| Indicator | TBBK | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 59.44 | 53.38 |
| Support Level | $65.95 | $90.40 |
| Resistance Level | $70.95 | $94.51 |
| Average True Range (ATR) | 1.91 | 3.70 |
| MACD | 0.89 | -0.60 |
| Stochastic Oscillator | 73.38 | 32.55 |
The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, specialty finance (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Specialty finance includes REBL (real estate bridge lending) comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.